

March 10, 1971

Dr. Max Streifler  
Head, Department of Neurology  
Municipal Governmental Medical Center  
Ichllov Hospital  
Tel-Aviv, Israel

Dear Max,

Your kind invitation to attend the conference on prolonged drug usage and the fetus was most welcome. I would like to attend, as the problem is a critical one. My laboratory, however, has no data on this problem and we will be unable to contribute to the proceedings.

We may, however, be able to send an observer, and I would appreciate a copy of the definitive program when it is available.

Our EEG profiles of psychoactive drugs have been successful in classifying some new drugs (thiothixene, cyclazocine, doxepin), in showing the bioavailability and equivalence of two dosage forms of doxepin, and of the capsule and concentrate thiothixene. We are now studying some new, numbered drugs and believe the technique will have more general applications.

In addiction research, we are the principal agency studying the narcotic antagonists (cyclazocine and naloxone) for opiate dependence; and, because of our local concern, the neurophysiology of cannabis.

It is a busy time, and if I can reach Israel in September, I will try to audit the sessions. I look forward to seeing you again.

My best regards.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kt